Zundelevich, Adi Dadiani, Maya Kahana-Edwin, Smadar Itay, Amit Sella, Tal Gadot, Moran Cesarkas, Karen Farage-Barhom, Sarit Saar, Efrat Glick Eyal, Eran
...
Published in
Breast Cancer Research
BackgroundEmerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%) but are relatively common (10–50%) in metastatic, endocrine therapy-resistant cancers and are associated with a shorter progression-free survival. Little ...
Pancholi, Sunil Leal, Mariana Ferreira Ribas, Ricardo Simigdala, Nikiana Schuster, Eugene Chateau-Joubert, Sophie Zabaglo, Lila Hills, Margaret Dodson, Andrew Gao, Qiong
...
Published in
Breast Cancer Research
After publication of the original article [1], we were notified that an author’s surname has been erroneously spelled. Elisabetta Maragoni’s family name should be replaced with Marangoni.
Ocaña, Alberto Amir, Eitan Pandiella, Atanasio
Published in
Breast Cancer Research
BackgroundThere has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).MethodsThrough a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) ...
de Ruijter, Tim C. van der Heide, Frank Smits, Kim M. Aarts, Maureen J. van Engeland, Manon Heijnen, Vivianne C. G.
Published in
Breast Cancer Research
BackgroundIn patients with hormone receptor-positive breast cancer, differentiating between patients with a low and a high risk of recurrence is an ongoing challenge. In current practice, prognostic clinical parameters are used for risk prediction. DNA methylation markers have been proven to be of additional prognostic value in several cancer types...
Jaber, Mustafa I. Song, Bing Taylor, Clive Vaske, Charles J. Benz, Stephen C. Rabizadeh, Shahrooz Soon-Shiong, Patrick Szeto, Christopher W.
Published in
Breast Cancer Research
BackgroundBreast cancer intrinsic molecular subtype (IMS) as classified by the expression-based PAM50 assay is considered a strong prognostic feature, even when controlled for by standard clinicopathological features such as age, grade, and nodal status, yet the molecular testing required to elucidate these subtypes is not routinely performed. Furt...
Chaudhary, Pankaj Gibbs, Lee D. Maji, Sayantan Lewis, Cheryl M. Suzuki, Sumihiro Vishwanatha, Jamboor K.
Published in
Breast Cancer Research
BackgroundLimited information is available on biomarker(s) for triple-negative breast cancer (TNBC) that can address the higher incidence and aggressiveness of TNBC in African-American (AA) women. Our previous studies have demonstrated annexin A2 (AnxA2) association with exosomes which promotes angiogenesis and metastasis. Therefore, our goal was t...
Wennstig, Anna-Karin Wadsten, Charlotta Garmo, Hans Fredriksson, Irma Blomqvist, Carl Holmberg, Lars Nilsson, Greger Sund, Malin
Published in
Breast Cancer Research
BackgroundAdjuvant radiotherapy (RT) for breast cancer (BC) has been associated with an increased risk of ischemic heart disease (IHD). We examined the incidence of IHD in a large population-based cohort of women with BC.MethodsThe Breast Cancer DataBase Sweden (BCBaSe) includes all women diagnosed with BC from 1992 to 2012 (n = 60,217) and age-mat...
Jacobs, Samuel A. Robidoux, André Abraham, Jame Pérez-Garcia, José Manuel La Verde, Nicla Orcutt, James M. Cazzaniga, Marina E. Piette, Fanny Antolín, Silvia Aguirre, Elena
...
Published in
Breast Cancer Research
After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.
Hogervorst, F. B. L. Collée, J. M. van Asperen, C. J. Mensenkamp, A. R. Ausems, M. G. E. M. Meijers-Heijboer, H. E. J. van Engelen, K. Blok, M. J. Oosterwijk, J. C. Verloop, J.
...
Published in
Breast Cancer Research
BackgroundThe effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have n...
Lewis, Kyle Kiepas, Alex Hudson, Jesse Senecal, Julien Ha, Jacqueline R. Voorand, Elena Annis, Matthew G. Sabourin, Valerie Ahn, Ryuhjin La Selva, Rachel
...
Published in
Breast Cancer Research
BackgroundThe p66ShcA redox protein is the longest isoform of the Shc1 gene and is variably expressed in breast cancers. In response to a variety of stress stimuli, p66ShcA becomes phosphorylated on serine 36, which allows it to translocate from the cytoplasm to the mitochondria where it stimulates the formation of reactive oxygen species (ROS). Co...
